Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Lymphoma, Lymphoma, Hematology, Hematology, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 10/1/2017 |
| Start Date: | October 7, 2014 |
| End Date: | August 29, 2016 |
A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as
measured by the absence of graft failure at day 42 in excess of that currently observed with
double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA)
conditioning.
measured by the absence of graft failure at day 42 in excess of that currently observed with
double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA)
conditioning.
Inclusion Criteria:
- Patients with a diagnosis that qualifies them for UCBT
- Adequate organ function
- Availability of eligible donor material
Exclusion Criteria:
- Pregnancy or breastfeeding women and women of child-bearing potential unless two
acceptable forms of contraception are being used
- Human immunodeficiency virus (HIV) infection
- Active infection
We found this trial at
1
site
Click here to add this to my saved trials
